Inside IP Autumn Winter 2017
Features a roundup of the latest cases and developments in IP.
Actavis v Eli Lilly Supreme Court Decision – the impact on intellectual property – Tim Russell and Chris Newcombe discuss the landmark decision and more specifically the issue of equivalents.
EU trade mark reform – A number of important changes to the EU trade mark regime came into force on 1 October 2017. David Yeomans gives a brief round-up.
Hot topic: Plausibility – Siân Gill, Anwar Gilani and Christopher Newcombe discuss the importance and significance of ensuring patent applications relate to a “plausible” invention, despite the fact that plausibility is not a ground for invalidity according to the European Patent Convention or the UK Patents Act.
The growing influence of blockchain – As the number of blockchain-related patent applications rise, Henry Aldridge discusses the interest and investment blockchain has recently received and how this is being realised across industries.
Undisclosed disclaimers at the EPO – Chris Hunter explains the current approach when making an amendment to a European Patent application and discusses the future outlook.
Intelligent patents for artificial intelligence – Although patents are frequently granted for AI-related inventions, James Varley, Richard Kennedy and Andrew Godley present some of the obstacles and factors affecting patentability, and further explain which principles should be considered when making a patent application.
Practical implications of G1/15 – Tim Russell looks at the effect the decision on poisonous priorities and toxic divisions has had on the assessment of inventive step in which prior art has been published between the priority date and the filing date of a European patent/patent application.
Funding in the UK Life Science sector – Kate McNamara details the steps the UK Government is taking to ensure continued growth in the Life Science sector.
Venner Shipley News
The future of medical treatment – precision medicine – Matt Handley discusses the future of medial treatment and the approach for patent applications relating to precision medicine.
IP valuation – Rob Cork analyses the strengths and weaknesses of the different approaches to putting a value on IP and why choosing the correct method is paramount.
Change to the law on groundless threats – Julia McFarlane and Kate Woolhouse discuss the new legislation on unjustified threats across patents, trade marks and design rights.
EPO changes approach to the patentability of products of essentially biological processes – Matt Handley discusses the changes as biological processes are no longer patentable in Europe.
Sale of grey goods is a criminal offence – Camilla Sexton demonstrates how a wronged trade mark owner can seek redress.
3D printing – the real story – Robert Peake, Ashley Roughton and James Plunkett examine some of the challenges in protecting potential patent rights and how related intellectual property rights may play a key role.
UPC update – Siân Gill provides an update on the Unitary Patent Court following the delay in its ratification.
